Marc Van Dijk News Today

Get latest articles and stories on Science at LatestLY. A novel form of cell therapy may help patients who are critically ill with acute respiratory distress syndrome (ARDS) brought on by severe COVID-19, according to a study. Science News | Study Finds How New Type of Cell Therapy Help ARDS Patients.

A new cancer drug could improve the prognosis for patients whose lungs have been severely damaged by Covid.

Promising trial results indicate that a new type of cell therapy could improve the prognosis of those who are critically ill with acute respiratory distress syndrome (ARDS) resulting from severe Covid-19.

The study shows that a new type of cell therapy can help in improve patients with acute respiratory distress syndrome (ARDS) caused by severe COVID-19. | Health

Treatment with agenT-797 Showed Improved Survival in Severe Respiratory DistressNEW YORK, Feb. 06, 2024 -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the...

Initial trial suggests invariant natural killer cell therapy improves survival. Promising trial results indicate that a new type of cell therapy could improve the prognosis of those who are critically ill with acute respiratory distress syndrome (ARDS) resulting from severe COVID-19. Published i

ARDS is a life-threatening disease that occurs when a person’s lungs are not working properly.

<p>An initial trial suggests that a new drug, originally developed for use with cancer patients, could improve the survival of patients with acute respiratory distress syndrome (ARDS). The patients in the trial were all critically unwell with ARDS, caused by severe Covid-19, and the invariant natural killer T (iNKT) cell therapy triggered an immune response in these individuals. The results are published in the journal <em>Nature Communications.</em></p>

(2022-08-09 | NDAQ:INKT) MiNK Therapeutics Reports Corporate Update and Second Quarter 2022 Financial Results

Novel stromal-CAR-iNKT shows activity in solid tumors; FIH planned for 2023Clinical presentation of AgenT-797 in solid tumors, myeloma, and ARDS planned...